Zhong Yuan

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 11

Top Topics

Venous Thromboembolism

Direct Oral Anticoagulants

Top Venues

Journal of the American Heart Association

Diabetes, obesity & metabolism

Endocrinology, diabetes & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
James Weaver, Azza Shoaib, Huy Q Truong, Leila Larbi, Shujian Wu, Peter Wildgoose, Gowtham Rao, Amy Freedman, Lu Wang, Zhong Yuan, Elliot Barnathan
Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA. Drug safety 44 (4) (2021)
Lu Wang, Erica A Voss, James Weaver, Laura Hester, Zhong Yuan, Frank DeFalco, Martijn J Schuemie, Patrick B Ryan, Don Sun, Amy Freedman, Maria Alba, Joan Lind, Gary Meininger, Jesse A Berlin, Norman Rosenthal
Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. Pharmacoepidemiology and drug safety 28 (12) (2019)
Jacob A Udell, Zhong Yuan, Patrick B Ryan, Toni Rush, Nicholas M Sicignano, Michael Galitz, Norman Rosenthal
Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study. Endocrinology, diabetes & metabolism 3 (1) (2019)
Patrick B Ryan, John B Buse, Martijn J Schuemie, Frank DeFalco, Zhong Yuan, Paul E Stang, Jesse A Berlin, Norman Rosenthal
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes, obesity & metabolism 20 (11) (2018)
Zhong Yuan, Frank J DeFalco, Patrick B Ryan, Martijn J Schuemie, Paul E Stang, Jesse A Berlin, Mehul Desai, Norm Rosenthal
Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. Diabetes, obesity & metabolism 20 (3) (2017)